Prenatal Labs Deep Dive: First Trimester Through Delivery

 

Prenatal Labs Deep Dive: First Trimester Through Delivery

NIPT sensitivity by condition, the GDM screening controversy, Rh typing pitfalls, and the labs that must happen three times now.

First Prenatal Visit Labs

Test	Why	Key Pitfall
CBC	Screen for anemia, thrombocytopenia, establish baseline MCV	Physiologic anemia of pregnancy (hemodilution) begins in 2nd trimester; don't treat mild drops in Hgb without iron studies
Blood type + Rh + antibody screen	Identify Rh-negative mothers; detect alloantibodies that could cause hemolytic disease of the newborn	Rh-negative mothers need RhoGAM at 28 weeks AND within 72 hours of delivery if baby is Rh-positive. Also after any sensitizing event (miscarriage, amniocentesis, trauma, ectopic).
HIV (4th-gen)	Universal screening. Early detection enables treatment to prevent vertical transmission.	Opt-out screening is the standard. Repeat in 3rd trimester for high-risk patients.
Syphilis (RPR or treponemal screen)	Universal. Now recommended ×3: first visit, 28 weeks, delivery.	Congenital syphilis has surged. Missing this kills babies. Non-negotiable ×3 screening.
Hepatitis B (HBsAg)	Identify carriers for neonatal prophylaxis (HBIG + vaccine at birth)	Even vaccinated mothers can be carriers if vaccination was incomplete or they were infected before vaccination.
HCV antibody	Universal screening in pregnancy per 2020 CDC recommendations	If positive, confirm with HCV RNA. Vertical transmission rate is ~5.8% in viremic mothers.
Rubella IgG	Confirm immunity. Congenital rubella syndrome is devastating.	Cannot vaccinate during pregnancy (live vaccine). If non-immune, vaccinate postpartum.
Urinalysis + culture	Screen for asymptomatic bacteriuria (ASB)—one of the few populations where ASB IS treated	Untreated ASB in pregnancy increases pyelonephritis risk 20–30 fold. Treat all positive cultures.
TSH	Screen for thyroid dysfunction (particularly if symptomatic or high-risk)	Use trimester-specific ranges. TSH normally drops in first trimester from HCG stimulation.
GC/CT NAAT	Screen for gonorrhea and chlamydia at first visit; repeat in 3rd trimester if high-risk	Untreated infections cause preterm labor, neonatal ophthalmia, pneumonia

Prenatal Genetic Screening

Cell-Free DNA (NIPT)

Non-invasive prenatal testing analyzes fetal DNA fragments in maternal blood. Can be done as early as 10 weeks. Now offered to ALL pregnant patients regardless of age or risk (per ACOG 2020).

Condition	Detection Rate	False-Positive Rate	Key Point
Trisomy 21 (Down syndrome)	>99%	<0.1%	Best non-invasive screening test available
Trisomy 18 (Edwards)	97–99%	<0.1%	High detection rate but confirmatory testing still needed
Trisomy 13 (Patau)	87–99%	<0.1%	Slightly lower sensitivity than T21
Sex chromosome aneuploidies	90–97%	Higher than trisomies	Turner's, Klinefelter's, etc. More false positives.
Microdeletions	Variable (60–80%)	Higher	22q11.2 (DiGeorge), 1p36, etc. PPV is LOW in average-risk populations. Many experts caution against routine microdeletion screening.

NIPT Is Screening, Not Diagnostic

A positive NIPT requires confirmatory diagnostic testing (amniocentesis or CVS with karyotype) before any irreversible decisions. NIPT has excellent negative predictive value but the positive predictive value depends on maternal age and prevalence—in low-risk populations, a significant proportion of "positive" results are false positives. Never terminate a pregnancy based on NIPT alone.

First Trimester Screen (Combined)

Nuchal translucency ultrasound + PAPP-A + free beta-hCG (weeks 11–13). Detection rate for T21: ~85%. Being largely supplanted by NIPT but still used in some settings, especially combined with NIPT for higher accuracy or when NIPT is inconclusive.

Quad Screen (Second Trimester)

AFP, hCG, estriol, inhibin A (weeks 15–22). Detection rate for T21: ~80%. Also screens for neural tube defects (elevated AFP) and trisomy 18. Still relevant for patients who present late for care or decline NIPT. Low AFP + other pattern abnormalities = screen positive, not diagnostic.

Gestational Diabetes Screening

The Two Approaches

• One-step (75g OGTT): Fasting, 1-hour, and 2-hour glucose. Used by IADPSG/WHO criteria. One abnormal value = GDM diagnosis. More sensitive, diagnoses more GDM, but debate continues over whether treating the additional cases improves outcomes.
• Two-step (most common in US): 50g glucose challenge test (GCT) as screen (no fasting required); if ≥130–140, follow with 100g 3-hour OGTT. Two abnormal values = GDM. ACOG endorses the two-step approach.

Screen at 24–28 weeks. Screen earlier if high-risk (BMI ≥30, prior GDM, PCOS, strong family history, HbA1c ≥5.7 at first visit). HbA1c is NOT recommended for GDM screening—it lacks sensitivity in pregnancy.

Third Trimester & Delivery Labs

• GBS culture (35–37 weeks): Vaginal-rectal swab. Positive patients receive intrapartum penicillin prophylaxis. GBS is the leading cause of early-onset neonatal sepsis.
• Repeat syphilis: At ~28 weeks and again at delivery. Non-negotiable given the congenital syphilis crisis.
• Repeat HIV: At delivery for high-risk patients or those with no documented test during pregnancy.
• Repeat antibody screen: At 28 weeks in Rh-negative mothers (before RhoGAM administration).
• CBC: Repeat in 3rd trimester to assess for anemia before delivery.

The Pitfalls Summary

• Syphilis screening ×3 is now the standard—a single screen at the first visit is no longer sufficient.
• NIPT is screening, not diagnostic—always confirm positive results with amniocentesis/CVS.
• Microdeletion screening on NIPT has low PPV in low-risk patients—counsel carefully before including these panels.
• HbA1c is not used for GDM screening—use glucose challenge/OGTT.
• Rh-negative mothers need RhoGAM at every sensitizing event, not just at 28 weeks and delivery.
• Asymptomatic bacteriuria in pregnancy MUST be treated—this is the exception to the "don't treat ASB" rule.
• Thyroid ranges are trimester-specific—don't use non-pregnant reference ranges in the first trimester.

Bottom Line

Prenatal labs are a comprehensive, time-sensitive program that runs from the first prenatal visit through delivery. The landscape has shifted with universal HCV screening, triple syphilis screening, NIPT for all pregnancies, and evolving GDM screening approaches. Know the timing, know the confirmatory steps for positive screens, and never miss syphilis or GBS.

Stay sharp out there.

Drug Levels & Therapeutic Monitoring: Timing, Targets, and the Mistakes That Cause Toxicity

 

Drug Levels & Therapeutic Monitoring: Timing, Targets, and the Mistakes That Cause Toxicity

Vancomycin has gone AUC/MIC. Phenytoin needs albumin correction. And lithium levels drawn at the wrong time are useless.

NPs in primary care co-manage patients on narrow therapeutic index medications constantly—anticonvulsants, lithium, digoxin, immunosuppressants, and antibiotics. Getting the timing wrong on a drug level makes the result uninterpretable. Getting the target wrong leads to toxicity or treatment failure.

Quick-Reference: Key Drugs

Drug	Therapeutic Range	When to Draw	Key Pitfall
Vancomycin	AUC/MIC 400–600 (current standard); trough 15–20 is outdated for serious MRSA but still used in some settings	AUC requires 2 levels (1–2 hr post-infusion + trough). For trough-only: draw 30 min before next dose.	AUC/MIC monitoring is now the 2020 ASHP/IDSA guideline standard. Trough-only monitoring overexposes patients to nephrotoxicity.
Digoxin	0.8–2.0 ng/mL (HF benefit at lower range 0.5–0.9)	At least 6 hours post-dose (distribution phase). Ideal: immediately before next dose.	Toxicity risk increases with hypokalemia, hypomagnesemia, hypothyroidism, and renal impairment. Always check K+ and Mg with digoxin levels.
Lithium	0.6–1.2 mEq/L (acute mania: up to 1.5)	12 hours post-dose (standardized timing is critical)	Dehydration, NSAIDs, ACE inhibitors, and thiazides all increase lithium levels. Toxicity is life-threatening. Monitor renal function and TSH regularly.
Phenytoin	10–20 mcg/mL (total); 1–2 mcg/mL (free)	Trough (before next dose). Steady state in 7–10 days.	Correct for albumin: Adjusted phenytoin = measured level / (0.2 × albumin + 0.1). In hypoalbuminemia, total phenytoin is falsely low but the free (active) level may be therapeutic or toxic. Order free phenytoin in hypoalbuminemic or uremic patients.
Valproic acid	50–100 mcg/mL	Trough. Steady state in 2–4 days.	Monitor LFTs and CBC (hepatotoxicity, thrombocytopenia). Highly protein-bound—free levels needed in hypoalbuminemia.
Carbamazepine	4–12 mcg/mL	Trough. Steady state in 2–4 weeks (auto-induction).	Auto-induces its own metabolism—levels drop after 2–4 weeks even at the same dose. Recheck after auto-induction period.
Methotrexate (low-dose)	No routine level monitoring for low-dose (rheumatic/dermatologic use)	N/A for weekly dosing	Monitor CBC, LFTs, creatinine, and albumin. Toxicity manifests as cytopenias, hepatotoxicity, pneumonitis—not as a "high level." Supplement with folic acid 1 mg daily.
Tacrolimus	5–15 ng/mL (varies by organ/time post-transplant)	Trough (12 hours post-dose, immediately before next dose)	Highly variable metabolism. CYP3A4 interactions are extensive (azoles increase levels; carbamazepine, phenytoin decrease). Monitor renal function, glucose, K+, Mg.

The Universal Rules

• Wait for steady state before checking levels (4–5 half-lives after starting or dose change).
• Timing matters: Trough levels are drawn immediately before the next dose. Drawing at the wrong time makes the result uninterpretable.
• Always check renal function with renally cleared drugs (vancomycin, lithium, digoxin, methotrexate).
• Always check albumin with highly protein-bound drugs (phenytoin, valproic acid).
• Drug interactions: CYP450 inducers (carbamazepine, phenytoin, rifampin) lower levels of co-administered drugs. CYP450 inhibitors (azoles, macrolides, grapefruit) raise them.

Bottom Line

Drug level monitoring is about timing, context, and correction factors. A phenytoin level without albumin correction is meaningless. A lithium level drawn 4 hours post-dose is uninterpretable. A vancomycin trough without considering AUC/MIC is outdated. And for methotrexate, you don't monitor levels—you monitor toxicity through labs. Get the timing right, check the renal function, and always ask "is this level drawn correctly?"

Stay sharp out there.

Pancreatic Enzymes: Lipase Wins, Amylase Is Overrated, and DKA Fakes Pancreatitis

 

Pancreatic Enzymes: Lipase Wins, Amylase Is Overrated, and DKA Fakes Pancreatitis

One enzyme is enough for diagnosis. The other one misleads you. And the magnitude doesn't predict severity.

Lipase vs. Amylase: Lipase Wins

Lipase is the preferred test for diagnosing acute pancreatitis. It's more sensitive (82–100%) and more specific (82–99%) than amylase. It rises within 4–8 hours, peaks at 24 hours, and remains elevated for 8–14 days (longer than amylase). Current ACG guidelines recommend lipase as the sole enzymatic criterion—amylase adds nothing and is no longer recommended as a standalone test for pancreatitis.

Acute pancreatitis is diagnosed when 2 of 3 criteria are met: (1) characteristic abdominal pain, (2) lipase ≥3× upper limit of normal, (3) characteristic findings on imaging. Most cases can be diagnosed without imaging if pain + lipase are both positive.

The Pitfalls

1. Amylase Has Too Many Non-Pancreatic Sources

Amylase is produced by the salivary glands, fallopian tubes, lungs, and small intestine—not just the pancreas. Elevated amylase can be caused by: parotitis (mumps), bowel obstruction, perforated ulcer, ectopic pregnancy, renal failure (decreased clearance), macroamylasemia (a benign condition where amylase binds to immunoglobulins and stays elevated chronically). If you only order amylase, you'll over-diagnose pancreatitis.

2. DKA Causes Elevated Lipase Without True Pancreatitis

The DKA Trap

Up to 16–25% of DKA patients have lipase >3× ULN without radiographic pancreatitis. The mechanism is likely metabolic (ketoacidosis + dehydration causing pancreatic ischemia) rather than true inflammatory pancreatitis. Don't diagnose pancreatitis in DKA based on lipase alone. Correlate with imaging and clinical presentation. If the abdominal pain resolves with DKA treatment, it wasn't pancreatitis.

3. Magnitude Doesn't Predict Severity

A lipase of 5,000 doesn't mean worse pancreatitis than a lipase of 500. The degree of elevation does NOT correlate with disease severity, complications, or prognosis. Severity is assessed by clinical criteria (BISAP score, Ranson's criteria, CT severity index), not enzyme levels.

4. Chronic Pancreatitis May Have Normal Lipase

In advanced chronic pancreatitis, the gland is so fibrosed and atrophied that it can no longer produce enough enzyme to elevate the lipase during acute exacerbations. A "burned-out pancreas" will have normal lipase even during pain flares. Diagnose chronic pancreatitis by imaging (calcifications on CT, pancreatic duct changes on MRCP).

5. Renal Failure Elevates Both Enzymes

Both lipase and amylase are renally cleared. CKD/ESRD patients commonly have chronically elevated levels (typically 2–3× ULN) without pancreatitis. Use clinical presentation and imaging, not enzyme levels alone, to diagnose pancreatitis in renal patients.

6. Macroamylasemia

A benign condition where amylase forms complexes with immunoglobulins that are too large for renal clearance, causing chronically elevated serum amylase. Lipase is normal. Diagnose by checking amylase-creatinine clearance ratio (low in macroamylasemia) or by serum amylase electrophoresis. This is one more reason lipase is superior—macroamylasemia doesn't affect lipase.

Bottom Line

Order lipase, not amylase. Don't diagnose pancreatitis in DKA based on lipase alone. The magnitude doesn't predict severity. Chronic pancreatitis can have normal enzymes. And CKD patients will have chronically elevated baseline levels. Acute pancreatitis is a clinical diagnosis supported by lipase, not a lipase diagnosis supported by pain.

Stay sharp out there.

Procalcitonin: When It Helps, When It Doesn't, and When It Fools You

 

Procalcitonin: When It Helps, When It Doesn't, and When It Fools You

The antibiotic stewardship tool that's powerful in the right context and useless in the wrong one.

Procalcitonin (PCT) is a peptide precursor of calcitonin that rises specifically in response to bacterial infection and remains low in viral infections and most autoimmune flares. It's gained traction as an antibiotic stewardship tool, but it's only useful in specific clinical scenarios—and ordering it indiscriminately creates more confusion than clarity.

How It Works

In health, PCT is produced only by thyroid C cells and is undetectable (<0.05 ng/mL). During bacterial infection, virtually every tissue in the body begins producing PCT in response to bacterial endotoxins and pro-inflammatory cytokines. Viral infections do NOT trigger this response (interferon-gamma actually suppresses PCT production), creating the bacterial-vs-viral distinction that makes PCT clinically useful.

Where PCT Changes Management (Evidence-Based)

• Lower respiratory tract infections: The strongest evidence. PCT-guided algorithms reduce antibiotic use in community-acquired pneumonia, acute bronchitis, and COPD exacerbations without increasing adverse outcomes. PCT <0.25 ng/mL strongly argues against bacterial pneumonia.
• Sepsis: PCT >0.5 supports bacterial sepsis. Serial PCT trending downward guides antibiotic de-escalation and discontinuation. Many ICU protocols use PCT to shorten antibiotic courses by 2–3 days.
• Neonatal sepsis: PCT at birth helps guide antibiotic duration in suspected early-onset neonatal sepsis (rises within 6–12 hours of infection).

Where PCT Does NOT Help

• UTI: PCT is unreliable for diagnosing UTI; localized infections don't always raise systemic PCT. Exception: pyelonephritis with systemic involvement may elevate PCT.
• Skin and soft tissue infections: Cellulitis, abscesses—PCT doesn't add to clinical assessment.
• Immunocompromised patients: Neutropenic fever, transplant recipients—PCT may be blunted or unreliable.
• Post-surgical patients: PCT rises after major surgery (especially cardiac, abdominal) as a nonspecific inflammatory response, limiting its specificity.

The Pitfalls

False Elevations (Non-Bacterial Causes)

• Major surgery or trauma (first 24–48 hours)
• Medullary thyroid carcinoma (C cells produce PCT constitutively)
• Severe burns, heat stroke
• Cardiogenic shock (without infection)
• Some autoimmune conditions: Kawasaki disease, anti-MDA5 dermatomyositis with severe inflammation, and Adult-onset Still's disease can elevate PCT
• Neonates: physiologic rise in the first 24–48 hours of life (age-specific norms required)

The Autoimmune Confounder

Most autoimmune flares (SLE, RA, vasculitis) do NOT raise PCT significantly, which makes it useful for distinguishing flare from infection in these patients. However, there are exceptions: severe systemic inflammation from macrophage activation syndrome (MAS), Kawasaki disease, and some inflammatory myopathies can elevate PCT without bacterial infection. Use it as one piece of the puzzle, not a standalone rule-out.

Interpretation Thresholds

PCT Level	Interpretation
<0.1 ng/mL	Bacterial infection very unlikely. Consider withholding/stopping antibiotics.
0.1–0.25	Bacterial infection unlikely. Antibiotics generally not recommended.
0.25–0.5	Possible bacterial infection. Consider antibiotics based on clinical context.
>0.5	Bacterial infection likely. Initiate/continue antibiotics.
>2.0	High likelihood of severe bacterial infection/sepsis.
>10	Severe sepsis/septic shock. Very high mortality risk.

Bottom Line

PCT is a powerful antibiotic stewardship tool when used in the right context: lower respiratory tract infections and sepsis. It's not useful for UTI, cellulitis, or post-surgical fever. It can help distinguish autoimmune flare from infection in your rheumatic patients (with exceptions). And the trend matters more than the single value—a PCT that's falling supports de-escalation; one that's rising demands investigation.

Stay sharp out there.

Hemoglobin Electrophoresis & Sickle Cell Testing: Interpreting the Patterns

 

Hemoglobin Electrophoresis & Sickle Cell Testing: Interpreting the Patterns

Trait vs. disease, thalassemia clues on the CBC, and why the newborn screen needs follow-up.

Hemoglobin electrophoresis separates hemoglobin variants by their electrical charge, identifying the type and proportion of each hemoglobin present. It's the definitive test for diagnosing hemoglobinopathies—but it's also one of the most misunderstood results in primary care.

Normal Hemoglobin Composition

• HbA (adult hemoglobin): 95–98% (two alpha + two beta globin chains)
• HbA2: 2–3.5% (two alpha + two delta chains)
• HbF (fetal hemoglobin): <1% in adults (two alpha + two gamma chains; predominates in utero and declines after birth)

The Key Patterns

Condition	HbA	HbS	HbA2	HbF	CBC Clues
Normal	95–98%	0	2–3.5%	<1%	Normal
Sickle cell trait (AS)	55–60%	35–45%	Normal	Normal	Usually normal CBC. No anemia. Benign in most contexts.
Sickle cell disease (SS)	0	80–95%	Normal	2–20%	Chronic hemolytic anemia, reticulocytosis, sickle cells on smear
HbSC disease	0	~45% S, ~45% C	Normal	Low	Milder anemia than SS; target cells on smear; still has vaso-occlusive crises
Beta-thalassemia trait	90–95%	0	>3.5%	Normal/slightly ↑	Microcytic anemia with normal RDW and elevated RBC count. Mentzer index (MCV/RBC) <13 favors thalassemia.
Beta-thalassemia major	0–10%	0	Variable	60–90%	Severe transfusion-dependent anemia from infancy
Alpha-thalassemia trait (2-gene deletion)	Normal pattern	0	Normal	Normal	Microcytic anemia with normal electrophoresis. Diagnosis by exclusion or genetic testing.
HbH disease (3-gene alpha deletion)	Reduced	0	Reduced	Normal	HbH (beta-4 tetramers) visible on special stain or HPLC. Moderate hemolytic anemia.

The Alpha-Thalassemia Trap

Alpha-thalassemia trait (1–2 gene deletions) has a completely normal hemoglobin electrophoresis. The only clues are microcytosis with normal iron studies and normal HbA2. If you've ruled out iron deficiency and the electrophoresis is normal, alpha-thalassemia trait is the diagnosis by exclusion (confirm with genetic testing if needed). This is extremely common in African American, Southeast Asian, and Mediterranean populations.

Thalassemia Trait vs. Iron Deficiency: The CBC Distinction

Both cause microcytic anemia. The CBC pattern distinguishes them:

• Iron deficiency: Low MCV, high RDW (unequal cells), low/normal RBC count, low ferritin, high TIBC
• Thalassemia trait: Low MCV, normal RDW (uniformly small cells), elevated RBC count, normal iron studies, elevated HbA2 (beta-thal) or normal electrophoresis (alpha-thal)

Newborn Screening Follow-Up

Pediatric Critical Point

All US states screen for hemoglobinopathies on the newborn metabolic panel. Results are reported as the hemoglobins detected in order of quantity: FA = normal (Fetal predominant, Adult present). FAS = sickle cell trait. FS = possible sickle cell disease (no HbA detected—needs urgent confirmatory testing). FSC = HbSC disease. Any abnormal newborn screen requires confirmatory hemoglobin electrophoresis by 2–3 months of age and genetic counseling. Early identification of sickle cell disease enables penicillin prophylaxis starting at 2 months, which dramatically reduces mortality from pneumococcal sepsis.

Connections to This Series

• HbA1c post: Hemoglobinopathies make A1c unreliable. HbS, HbC, HbE interfere with assays.
• CBC post: MCV + RDW + RBC count pattern distinguishes thalassemia from iron deficiency.
• Iron studies post: Always check iron studies before diagnosing thalassemia. Coexisting iron deficiency can mask thalassemia, and iron overload from transfusions is a major complication.

Bottom Line

Hemoglobin electrophoresis diagnoses sickle cell disease, beta-thalassemia, and hemoglobin variants definitively. Alpha-thalassemia trait is the exception—it has a normal electrophoresis and is diagnosed by exclusion. Use the CBC pattern (MCV, RDW, RBC count) to guide when to order electrophoresis, and always follow up abnormal newborn screens promptly.

Stay sharp out there.

Fecal Calprotectin & Hyperinflammation Markers: IBD vs. IBS, and When Ferritin >10,000 Is a Diagnosis

 

Fecal Calprotectin & Hyperinflammation Markers: IBD vs. IBS, and When Ferritin >10,000 Is a Diagnosis

The stool test that saves your patient a colonoscopy and the serum ferritin level that means macrophage activation, not iron overload.

Part 1: Fecal Calprotectin—IBD vs. IBS

Fecal calprotectin is a neutrophil-derived protein released into the gut lumen during intestinal inflammation. It's the single best non-invasive test for distinguishing inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS)—a distinction that saves patients from unnecessary colonoscopies and saves the healthcare system significant cost.

How to Use It

• Calprotectin <50 µg/g: IBD very unlikely. Supports IBS or functional GI disorder. Negative predictive value >95%.
• 50–150: Borderline. Repeat in 4–6 weeks. If persistently elevated, refer for GI evaluation.
• >150: Intestinal inflammation likely. Correlate with clinical picture. Refer for colonoscopy/endoscopy to differentiate Crohn's, UC, or other causes.
• >250: Strongly suggestive of active IBD.

Also useful for monitoring IBD activity: rising calprotectin in a known IBD patient may predict relapse before symptoms appear, enabling preemptive treatment adjustment.

Pitfalls

• NSAIDs cause intestinal inflammation and elevate calprotectin—stop NSAIDs for 2 weeks before testing.
• PPIs may mildly elevate calprotectin in some patients.
• GI infections (bacterial gastroenteritis) elevate calprotectin—test after the infection resolves.
• Colorectal cancer can elevate calprotectin—an elevated result in an older patient still warrants colonoscopy.
• Children <4 years have physiologically higher calprotectin levels; use age-adjusted thresholds.
• Celiac disease can mildly elevate calprotectin.

Part 2: Hyperinflammation Markers—When Ferritin Tells a Different Story

Ferritin as a Hyperinflammation Marker

In the iron studies post, we discussed ferritin as an acute-phase reactant that masks iron deficiency. But extremely elevated ferritin (>1,000–10,000+) is a different diagnostic entity—it signals macrophage activation and hyperinflammation, not iron overload.

Ferritin >10,000 = Think MAS or HLH

Hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) are life-threatening hyperinflammatory conditions where macrophages go into overdrive, phagocytosing blood cells and releasing massive cytokines. Ferritin >10,000 ng/mL is a classic diagnostic clue (sensitivity ~90% for HLH in children). Other features: high fevers, cytopenias, hepatosplenomegaly, elevated triglycerides, low fibrinogen, elevated soluble IL-2 receptor. MAS is the rheumatologic variant, most commonly complicating systemic JIA (children) or Adult-onset Still's disease.

Adult-Onset Still's Disease

Ferritin >1,000 (often >5,000–10,000+) in a young adult with quotidian (daily spiking) fevers, evanescent salmon-colored rash, arthritis, sore throat, and leukocytosis is Adult-onset Still's disease until proven otherwise. A unique feature: the glycosylated ferritin fraction drops to <20% (normal >50%), which helps confirm the diagnosis. This specialized test isn't available everywhere but is highly specific when obtainable.

Other Hyperinflammation Markers

• Soluble IL-2 receptor (sIL-2R/sCD25): Markedly elevated in HLH/MAS. Included in the HLH-2004 diagnostic criteria.
• Lactate dehydrogenase (LDH): Elevated in hemolysis, tissue destruction, and hyperinflammatory states. Non-specific but part of the pattern.
• Triglycerides: Paradoxically elevated in HLH/MAS (cytokine-mediated lipolysis suppression).
• Fibrinogen: Low in HLH/MAS (consumed by DIC-like process), which is the opposite of what you'd expect in inflammation (fibrinogen is normally an acute-phase reactant that rises).

Bottom Line

Fecal calprotectin is your primary care tool for distinguishing IBD from IBS non-invasively—a negative result (<50) has >95% NPV for ruling out IBD. Stop NSAIDs before testing. On the hyperinflammation side, learn to recognize the pattern: ferritin >10,000 + cytopenias + fevers + hepatosplenomegaly = HLH/MAS until proven otherwise. These are rare but lethal conditions where early recognition saves lives.

Stay sharp out there.

Uric Acid: The Gout Pitfall, the Asymptomatic Hyperuricemia Debate, and Tumor Lysis

 

Uric Acid: The Gout Pitfall, the Asymptomatic Hyperuricemia Debate, and Tumor Lysis

Uric acid is often NORMAL during a gout flare. Asymptomatic hyperuricemia almost never needs treatment. And yet both mistakes happen daily.

Uric acid is a deceptively simple lab that generates outsized confusion. The two most common errors: using it to rule out gout during an acute flare (when it's often normal) and treating asymptomatic hyperuricemia (which guidelines recommend against).

The #1 Pitfall: Normal Uric Acid During Acute Gout

During an acute gout flare, serum uric acid drops in up to 40% of patients due to the inflammatory response (IL-6 increases renal uric acid excretion) and redistribution of urate into the inflammatory joint. A normal serum uric acid does NOT rule out gout. The gold standard for acute gout diagnosis is synovial fluid analysis showing negatively birefringent monosodium urate crystals under polarized light. If you can't aspirate the joint, diagnose gout clinically (monoarticular, first MTP involvement, rapid onset, prior attacks, response to colchicine) and check uric acid 2–4 weeks after the flare resolves for a more accurate baseline.

Asymptomatic Hyperuricemia: Don't Treat It

Elevated uric acid (>6.8 mg/dL is the saturation point) without gout, tophi, or uric acid nephrolithiasis is asymptomatic hyperuricemia. Current ACR/EULAR guidelines recommend against urate-lowering therapy for asymptomatic hyperuricemia. There is no proven benefit in preventing gout, CKD progression, or cardiovascular events in this population. Most hyperuricemic patients never develop gout. Address modifiable factors: reduce alcohol (especially beer), limit purine-rich foods, stop or reduce thiazides/loop diuretics if possible, manage metabolic syndrome.

When Uric Acid Is Useful

• Establishing baseline for gout management: Check 2–4 weeks after a flare. Target <6 mg/dL (some guidelines say <5 for tophaceous gout) on urate-lowering therapy (allopurinol, febuxostat).
• Monitoring urate-lowering therapy: Titrate allopurinol to target uric acid, not to a fixed dose.
• Tumor lysis syndrome (TLS): Uric acid rises rapidly as tumor cells lyse (after chemotherapy for high-tumor-burden malignancies: ALL, Burkitt's, high-grade lymphomas). Elevated uric acid + hyperkalemia + hyperphosphatemia + hypocalcemia = TLS. Prevent with aggressive IV hydration, rasburicase, or allopurinol.
• Preeclampsia: Elevated uric acid is associated with preeclampsia severity, though it's a marker, not a diagnostic criterion.
• CKD monitoring: Uric acid rises as GFR declines. Whether treating hyperuricemia slows CKD progression remains debated—current evidence does not support routine treatment.

Medication Pitfalls

Thiazides and loop diuretics raise uric acid (decreased renal excretion). Losartan and fenofibrate lower it (uricosuric effects). Low-dose aspirin raises uric acid; high-dose aspirin lowers it. Consider these medication effects before attributing hyperuricemia to diet or genetics.

Bottom Line

Don't use uric acid to diagnose or exclude acute gout—it's unreliable during flares. Don't treat asymptomatic hyperuricemia. Do use it to monitor urate-lowering therapy (target <6) and watch for it in tumor lysis syndrome. And always check the medication list before blaming the patient's diet.

Stay sharp out there.